Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsKYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.
Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.
MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN
AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies
Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day
The HCPFive: Top News for Healthcare Providers from the Week of 11/16
1.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
2.
Relationship-building key to addressing oncologist shortages in rural care
3.
A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.
4.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
5.
Prostate cancer therapies: AI-based image analysis detects early organ damage
1.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
2.
Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon
3.
Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment
4.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
5.
Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation